| Budget Amount *help |
¥200,330,000 (Direct Cost: ¥154,100,000、Indirect Cost: ¥46,230,000)
Fiscal Year 2023: ¥36,790,000 (Direct Cost: ¥28,300,000、Indirect Cost: ¥8,490,000)
Fiscal Year 2022: ¥37,050,000 (Direct Cost: ¥28,500,000、Indirect Cost: ¥8,550,000)
Fiscal Year 2021: ¥38,480,000 (Direct Cost: ¥29,600,000、Indirect Cost: ¥8,880,000)
Fiscal Year 2020: ¥40,950,000 (Direct Cost: ¥31,500,000、Indirect Cost: ¥9,450,000)
Fiscal Year 2019: ¥47,060,000 (Direct Cost: ¥36,200,000、Indirect Cost: ¥10,860,000)
|
|---|
| Outline of Final Research Achievements |
We have conducted four major research projects simultaneously to discover cancer-specific biomarker enzymes that cannot be visualized by conventional methods, to achieve intraoperative rapid and precise fluorescence imaging, and to create innovative neutron capture therapy probes for the treatment and detection of deeply located micro cancers. First, for the logical design of fluorescence probes based on quantum chemical calculations and the creation of probe libraries, we established a molecular design method based on precise prediction of spirocyclization equilibrium constants by quantum chemical calculations and succeeded in developing a set of multicolor fluorescence probes. By creating a library of these fluorescence probes and applying them to clinical samples, we succeeded in discovering various cancer biomarker enzyme activities. (Other results will be reported later due to patent issues.)
|
